Daewoong Pharmaceutical Co. Ltd.
Clinical trials sponsored by Daewoong Pharmaceutical Co. Ltd., explained in plain language.
A South Korean pharmaceutical company producing prescription drugs and consumer health products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug aims to slow lung scarring in IPF Results expected Oct 2026 (estimated)
- Needle-Free semaglutide patch enters first human safety trial Results expected Oct 2026 (estimated)
- New autoimmune drug candidate takes first step in human tests Results expected Dec 2026 (estimated)
- New study tests apremilast for psoriasis relief Results expected Dec 2026 (estimated)
- 12,000-Patient study tests new cholesterol pill in real life Results expected Mar 2027 (estimated)
-
Experimental drug aims to slow lung scarring in IPF
Disease control OngoingThis phase 2 trial tests whether an experimental drug called DWN12088 can safely slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. About 102 adults aged 40 and older with stable IPF will be randomly assigne…
Phase 2 • Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Diabetes drug shows promise for weight loss in Real-World study
Disease control OngoingThis study is looking at whether enavogliflozin, a diabetes medication, can help people with type 2 diabetes lose weight. Researchers will track 200 adults over 24 weeks in regular doctor visits. The main goal is to see changes in body weight and BMI, along with safety.
Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jun 26, 2026 12:44 UTC
-
New diabetes drugs under Real-World watch: 15,000 patients enrolled
Disease control OngoingThis study is observing 15,000 adults with type 2 diabetes who are starting Envlo or Envlomet SR tablets. Researchers will check how well these drugs control blood sugar (HbA1c) over 24 weeks and monitor for side effects. The goal is to see if they work safely in everyday medical…
Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jun 26, 2026 12:40 UTC
-
Can a phone app help tame diabetes? new study investigates
Disease control OngoingThis study tests whether a smartphone app called WellCheck, linked to patients' electronic health records, can improve blood sugar, blood pressure, and weight in people with type 2 diabetes. About 471 adults will use the app either with their doctor's guidance or on their own. Th…
Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jun 26, 2026 12:36 UTC